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A great deal of evidence supports a role for mitochondrial dysfunction in the pathogenesis of Parkinson’s disease (PD), although
theorigin of the mitochondrial dysfunction in PD remains unclear. Expression of mitochondrial DNA (mtDNA) from PDpatients
in “cybrid” cell lines recapitulates the mitochondrial defect, implicating a role for mtDNA mutations, but the speciﬁc mutations
responsibleforthemitochondrialdysfunctioninPDhavebeendiﬃculttoidentify.SomaticmtDNApointmutationsanddeletions
accumulate with age and reach high levels in substantia nigra (SN) neurons. Mutations in mitochondrial DNA polymerase γ
(POLG) that lead to the accumulation of mtDNA mutations are associated with a premature aging phenotype in “mutator”
mice, although overt parkinsonism has not been reported in these mice, and with parkinsonism in humans. Together these data
support, but do not yet prove, the hypothesis that the accumulation of somatic mtDNA mutations in SN neurons contribute to
the pathogenesis of PD.
1. Evidence for Mitochondrial
DysfunctioninPD
A large body of evidence suggests that mitochondrial
dysfunction is a common pathological mechanism of neu-
rodegenerative diseases including PD. There is a signiﬁ-
cant decrease in complex I activity of the mitochondrial
electron transport chain and reduced immunohistochemical
staining for complex I subunits in the substantia nigra
(SN) from PD patients [1–4]. A recent meta-analysis of
genome-wide expression data from SN neurons of patients
with symptomatic and subclinical PD identiﬁed defects in
mitochondrial electron transport, glucose utilization and
sensing [5]. One key set of genes found in this study to
be underexpressed in the brains of PD patients is under
the control of the transcriptional coactivator peroxisome
proliferator-activated receptor gamma coactivator 1-alpha
(PGC-1α), a master regulator of mitochondrial biogenesis.
Moreover, functional imaging like PET and functional
magnetic resonance imaging (fMRI) show glucose metabolic
defect in the frontal cortex in PD patients [6, 7]. Together,
these and other data provide clear evidence for a defect in
mitochondrial metabolism in PD.
2. Mitochondrial Dysfunction:
Chicken orEgg?
Although evidence for defective mitochondrial energy
metabolism in PD is strong, such a defect theoretically
could be a consequence or marker of neurodegeneration
rather than a contributor to the pathogenesis of PD.
The most compelling evidence supporting a pathogenic
role for mitochondrial dysfunction in PD comes from
accidental human exposures to 1-methyl-4-phenyl-1,2,3,6-
tetrahydrodropyridine (MPTP), which causes parkinsonism
in human by inhibition of mitochondrial complex-I of
the electron transport chain [8, 9]. MPTP also inhibits
alpha-ketoglutaratedehydrogenase;thereforetherewassome
debate as to whether or not the mechanism behind MPTP
toxicity involved complex I inhibition [10]. This question
has since been addressed by the subsequent discovery
that chronic systemic administration of rotenone, a highly
speciﬁc complex-I inhibitor, causes highly selective and
progressive nigrostriatal dopaminergic degeneration and a
parkinsonian phenotype in rats, further implicating mito-
chondrial complex I dysfunction in PD pathogenesis [11–
13].2 Parkinson’s Disease
3.Originofthe Mitochondrial
Complex-I Defect in PD
The evidence cited above implicating a pathogenic role for
mitochondrial complex I dysfunction in PD has led to great
interest in understanding the origin of the complex I defect.
Cytoplasmic hybrid (cybrid) cell lines created by transferring
cytoplasmic contents including mitochondria from platelets
or enucleated donor cells into cells experimentally depleted
of endogenous mtDNA can be used to determine if a
mitochondrial defect results from mtDNA mutations versus
other causes (e.g., mitochondrial toxins or nuclear DNA
mutations)[14].CybridsexpressingmtDNAfromidiopathic
PD patients show reduced complex-I activity and increased
susceptibility to MPP+, suggesting that mtDNA encoded
defects in PD [15, 16]. Because cybrid cell lines share
the same nuclear DNA background and diﬀer only in the
source of their mtDNA, these data implicate stable change in
mtDNA (e.g., mutations) as a cause of the complex I defect
in PD. In contrast, cybrid cell lines expressing mtDNA from
subjects in the “Contursi” kindred who develop PD due to
an autosomal dominant mutation in the α-synuclein gene
do not manifest complex I deﬁciency [17]. This suggests
that a nuclear genetic mutation can cause PD in the absence
of mtDNA mutations, and that mtDNA mutations are
more likely to contribute to idiopathic PD than to less
common forms of PD associated with known nuclear genetic
mutations.
4.M it oc ho ndrialDN AandClassiﬁcatio n
of Mutations
These data from cybrids implicating mtDNA mutations in
the complex I defect in PD therefore led to the search
for inherited mtDNA mutations in PD patients. There are
three main classes of mtDNA mutations: ancient maternally
inherited polymorphisms that have given rise to various
mitochondrialhaplogroups,evolutionarilyrecentmaternally
inherited potentially pathogenic mutations, and somatic
mtDNA mutations that accumulate during the life of the
organism [18]. A number of studies have linked certain
mitochondrial haplogroups with increased or decreased risk
of PD in various populations of diﬀering ethnicity [19–
27]. Our laboratory found the G11778A mtDNA point
mutationinasubunitofmitochondrial complexIinafamily
with maternally inherited parkinsonism and multisystem
degeneration including nigral cell loss, demonstrating an
association between an inherited mtDNA mutation and
parkinsonism [28]. However, attempts to identify clearly
pathogenic inherited mtDNA mutations in PD patients by
direct sequencing of mtDNA have revealed that most PD
patients lack such mutations [29–31]. The common 10398G
variant of the NADH dehydrogenase 3 (ND3) gene (a
subunit of mitochondrial complex I), present in up to 40%
of Caucasians, has been reported to be present in a lower
percentage of Caucasian PD patients compared to matched
controls, suggesting a protective role in PD [32]. However,
althoughasimilarassociationwasidentiﬁedinanotherstudy
[33], others have not replicated this result [27, 29].
Thus, although mtDNA point mutations have been
found in rare families exhibiting parkinsonism [28, 34–39],
clearly pathogenic mutations have not been identiﬁed in the
vast majority of PD patients. Although a role of common
mtDNA variants and rare pathogenic point mutations
remains a possibility for some PD patients, these data led to
the hypothesis that somatic mtDNA mutations, which may
not be detectible by standard sequencing methods, might
contribute to the complex I defect in PD.
5. A Role for Somatic mtDNA Mutations
The term “somatic mutations” (also known as acquired
mutations) refers to DNA mutations that were not present
in the germ cells that gave rise to the organism, but occurred
later in development of the organism. Somatic mutations in
mtDNAmaytaketheformofsinglepointmutationsorsmall
or large mtDNA deletions. mtDNA point mutations and
mtDNA deletions can arise through separate mechanisms,
although both types of mutation are now thought to be
more commonly due to endogenous processes as opposed
to exposure to exogenous agents [40, 41]. Somatic mtDNA
point mutations may arise in three ways: ﬁrstly, base-
substitution mutations caused by mitochondrial polymerase
γ inﬁdelity [42, 43], and mitochondrial polymerase γ
replicating across damaged bases [40] may arise. Secondly,
the proximity of mtDNA to ROS generated from the electron
transport chain (ETC), as well as the lack of protective
histones [44], may lead to oxidative damage to mtDNA,
which can be highly mutagenic [45, 46]. Indeed, levels of
oxidative damage to mtDNA in the brain are much higher
than levels of damage to nuclear DNA, particularly in elderly
subjects [47]. It is possible that this is especially pronounced
in the SN where dopamine metabolism, high levels of iron,
and low levels of glutathione (an important antioxidant),
may create an environment especially high in oxidative stress
[48, 49]. Finally, although mitochondria lack nucleotide
excision repair mechanisms, the mitochondrial genome is
protectedbybaseexcisionrepairmechanisms[50].However,
a decline in the base excision repair mechanism has been
observed with age [51].
A number of hypotheses have been put forward for
how mtDNA deletions may occur: initially it was thought
that strand slippage during replication of mtDNA molecules
[52, 53] gave rise to deletions in mtDNA, but more recently
a theory that mtDNA deletions are created during the
repair of mtDNA double strand breaks has been proposed
[41]. Conclusive experimental evidence for either theory is
currently insuﬃcient.
6. Clonal Expansionof mtDNA
SomaticMutations
The term heteroplasmy refers to the instance where mtDNA
mutations aﬀect only a proportion of the mitochondrial
genome within a single cell, tissue, or organism. In contrast,
the term homoplasmy is used when an mtDNA mutation
aﬀects all copies of the mitochondrial genome withinParkinson’s Disease 3
a deﬁned unit. Heteroplasmic somatic mutations may
become functionally signiﬁcant for two reasons: ﬁrstly,
mtDNA mutations may undergo clonal expansion within
individual cells. Clonal expansion of mtDNA mutations
has been observed for both mtDNA deletions [54–56]
and mtDNA point mutations [57]; however, the mecha-
nisms behind clonal expansion are still under investigation.
The high mtDNA content per cell and dynamism of the
mitochondrial genome may be a contributing factor: each
mitochondrion may contain several mitochondrial genomes,
and each cell contains multiple mitochondria (the number
of which varies according to the energy requirements of the
cell), resulting in an estimated 103 to 104 copies of the mito-
chondrial genome per cell [58]. In addition, mitochondria
are dynamic organelles and frequently undergo fusion and
ﬁssion as well as frequent rounds of mtDNA replication
[59, 60]. This raises the possibility of clonal expansion
of a particular mtDNA mutation through random genetic
drift, which has been demonstrated experimentally after
induction of “relaxed” mtDNA replication [61], which refers
to replication of mitochondria in nondividing cells. In addi-
tion, theories of directed segregation have been proposed.
Directed segregation has been demonstrated to select against
mtDNA mutations [62] and seemingly paradoxically, to also
select for mutant mtDNA via selection for advantageous
replicative mechanisms [63]. A deﬁnitive answer to the
mechanisms behind clonal expansion is not yet available. It
is possible that there will be more than one mechanism and
that this may vary depending on the mitotic or postmitotic
nature of the cells [64].
7. Aggregate Burden of Somatic Mutations and
Failureof FunctionalComplementation
Once a certain “phenotypic threshold” of clonal expansion
has been reached (around 50%–95% of mtDNA copies
per cell depending on the mutation, cell type, and other
factors; [65–69] a deleterious mutation may lead to impaired
mitochondrial function [70, 71] as beyond that level,
functional mitochondrial complementation may no longer
provide restoration of functional ETC complexes [72]).
To elaborate further, the term “functional mitochon-
drial complementation” refers to the exchange of genetic
information between mitochondria to alleviate a respira-
tory deﬁcit caused by the mutation of an ETC gene in
one of the mitochondria [73]. mtDNA is packaged in
genetically autonomous mtDNA-protein complexes called
nucleoids [74–76], these are mobile elements that are located
throughout the mitochondrial genome [77] and include the
transcriptionfactorTFAM,mitochondrialpolymeraseγ,and
the mitochondrial helicase Twinkle [78]. Nucleoids work
t om a i n t a i nh e t e r o l o g o u sm t D N Aa sd i ﬀerent populations,
preventing intermixing between mtDNA populations [79].
However, complementation can occur in stably separate
nucleoid populations through transcomplementation by
transcripts and polypeptides from nonmutant mitochondria
freely diﬀusing through the mitochondrial matrix and
becoming translated or assembled into ETC complexes,
leading to a restoration of mitochondrial function [80].
Because functional complementation occurs in mito-
chondrial genomes, it is possible that the presence of
functional ETC complexes may phenotypically mask the
mtDNA mutational burden of the cell. Therefore, even when
the majority of the copies of a particular mitochondrial
gene within a single cell harbor a particular mutation, the
cell may remain healthy, although eventually clonal ex-
pansion or the accumulation of new mutations may lead
to a mutational burden that exceeds what the cell can
tolerate. This phenotypic threshold is reached when comple-
mentation is no longer suﬃcient to allow suﬃcient numbers
of normal mitochondrial complexes to be formed.
In addition to the clonal expansion of a single mito-
chondrial mutation, cellular respiration and organismal
health may also be aﬀected by the aggregate mutational
burden resulting from the net impact of a number of
diﬀerent individually rare mtDNA mutations. For example,
100 diﬀerent mtDNA mutations, each of which is present in
a mitochondrial genome at a frequency of 1%, leads to an
aggregate mutational burden of 100% (meaning an average
of 1 mutation per mitochondrial genome). The functional
consequences of this situation may be diﬀerent from the
impact of a single speciﬁc mutation clonally expanding to
reach 100% (homoplasmy), particularly with respect to the
potential role of complementation. Complementation still
may allow functional ETC complexes in the case of multiple
distinct mutations, whereas this may not be the case for the
clonally expanded mutation. This is the case, for example, if
the clonally expanded mutation aﬀects a critical amino acid,
making it impossible for that cell to make any functional
copies of that subunit. Thus, the phenotypic threshold may
bemuchhigherformultipleindividuallyraremutationsthan
for a single clonally expanded mutation.
8. Somatic mtDNA Mutationsinthe SN
The ﬁrst published study to quantify the number of multiple
somatic mtDNA point mutations in the SN used a highly
sensitive cloning and sequencing strategy to characterize the
aggregate burden of mtDNA mutations in the frontal cortex
and SN of postmortem tissue from PD patients as well as
young and old control subjects [71]. This study found that
aggregate levels of point mutations increased with age in
the frontal cortex of elderly subjects (65–91 years of age)
compared to young controls (age 1–24 years). However, this
study did not detect a statistically signiﬁcant increase in
the frequency of point mutations in the frontal cortex or
SN of PD patients compared to age-matched controls. The
authors hypothesized a number of reasons for this. Firstly,
the study used postmortem tissue, which likely represented
late stage PD. Therefore, the only dopaminergic neurons
included in the analysis were those few that survived to late-
stage PD when as many as 98% of the dopaminergic neurons
may have already been lost [81]. It is possible that these
neurons survived because they were somehow protected
from the accumulation of mtDNA mutations. Secondly,
these studies used brain tissue (as opposed to individual
neurons); therefore the glial contribution may have been
increased relative to the neuronal contribution in the PD4 Parkinson’s Disease
cases because of the scarcity of dopaminergic neurons in
late-stages of PD. This could have reduced the relative level
of mutations detected in the PD cases as the mean level of
mutations is greater in SN neurons compared to glia [82].
To determine whether the frequency of somatic mtDNA
point mutations diﬀered between SN neurons and glia, the
same authors performed a similarly sensitive cloning and
sequencing strategy on laser-capture microdissected single
neurons and glial cells from six control subjects [82]. This
studydidindeedshowthatthemeanlevelofsomaticmtDNA
point mutations in single neurons was signiﬁcantly higher
than the mean level in glia with extrapolation of the data
suggesting 3.3 somatic point mutations per mitochondrial
genome in neurons and 2.2 mutations per mitochondrial
genome in glia. In addition, this work demonstrated that
heteroplasmy is common in both the D-loop and coding
regions even at the level of single neurons and glia. Whether
or not somatic mtDNA point mutations reach higher levels
in SN neurons in PD remains an important question.
9. ND5 Somatic Mutationsin PD
Other studies have used a similar cloning and sequencing
approach to investigate the frequency of mtDNA complex
I somatic point mutations in PD patients and aging. One
study investigated mutational burden in all seven of the
mitochondrial genes encoding the complex I subunits in
frontal cortex tissue homogenates [83]. In agreement with
previous work [71], the authors found that there was
no signiﬁcant diﬀerence in the overall number of point
mutations between PD patients and controls. However, this
studyfoundthatthepercentageoftransitionswaslowerthan
in the previously published work at 39% in PD and 29% in
controls compared to 88% of the mutations found in the
previous work. The reasons for this apparent discrepancy
are not immediately clear. In addition, this work identiﬁed
low levels of somatic mutations in the ND5 gene that were
observed only in PD patients and not seen in controls
[83]. Although the same authors subsequently conﬁrmed
this ﬁnding in another set of PD samples [84], levels of
the mutations were quite low, generally less than 1%, well




In early 2006, back-to-back papers in Nature Genetics
reported the ﬁrst ﬁndings on the frequency of mtDNA
deletions in human SN neurons [85, 86]. Both groups used
cytochrome C oxidase (COX) deﬁciency in SN neurons
as a marker of a mitochondrial respiratory chain defect.
The Bender et al. study [85] used long-range PCR to
amplify mtDNA from COX-deﬁcient and control neurons,
and the Kraytsberg et al. study [86] developed a novel single-
molecule PCR technique to quantify the total cellular burden
of mtDNA deletions in COX-deﬁcient neurons harboring a
mitochondrial respiratory chain defect and control neurons.
Both studies found that mtDNA deletions were present
at higher levels in aged controls compared to younger
individuals and that these deletions were clonally expanded.
In addition, the work from Bender and colleagues identiﬁed
that mtDNA deletions were higher still in individuals with
Parkinson’s disease compared to aged controls (52.3% and
43.3% resp.), although the diﬀerence was of borderline
signiﬁcance (P = .06).
These ﬁndings of surprisingly high levels of clonally
expanded mtDNA deletions in SN neurons from elderly sub-
jects, and a correlation of mutations with COX-deﬁciency,
support the hypothesis that the age-related accumulation
of somatic mtDNA mutations may contribute to the aging
of the human brain and to the pathogenesis of Parkinson’s
disease. However, because these studies of human samples
can be only observational in nature, it is diﬃcult to accrue
deﬁnitive evidence for functional consequences of mtDNA
mutations. For such studies, the POLG “Mutator” mice are
informative.
11. Evidence from the POLG “Mutator” Mice
The mitochondrial theory of aging proposes that the accu-
mulation of mtDNA mutations lead to the aging process
andtoage-relatedneurodegenerativediseases[87].However,
experimentalevidenceinsupportofthisfundamentaltheory
of aging has been limited. Several years ago, two groups
reported that transgenic mice expressing a proofreading
deﬁcient form of POLG are phenotypically normal at birth
but accumulate very high levels of somatic mtDNA point
mutations as they age, resulting in a premature aging
phenotype that includes weight loss, reduced subcutaneous
fat,hairloss,thinningofbones,anemia,reducedfertility,and
early death [88, 89] .T h e s em i c ew e r eh e r a l d e da se v i d e n c e
in support of the mitochondrial theory of aging. However,
it has been argued that POLG mutator mice accumulate
mtDNA point mutation levels that are more than an order
of magnitude higher than typical levels in aged humans,
and so their aging-like phenotypes do not imply that levels
of mtDNA mutations achieved during normal aging are
functionallyrelevant[90].Furthermore,heterozygousPOLG
mutator mice also accumulate higher mtDNA mutation
l e v e l st h a ns e e ni nn o r m a la g e dm i c ea n dy e tl a c ka no v e r t
phenotype, leading to further questions as to the relevance
of these mice to the normal aging process [91].
In addition, the lack of overt parkinsonism in the POLG
mutator mice could be interpreted as arguing against a
role for somatic mtDNA mutations in PD. However, there
are several important caveats to this argument. It remains
possible that a more subtle phenotype may be present in
heterozygous POLG mutator mice. For example, testing on
behavioral measures sensitive to dopamine deﬁciency has
not been reported. Also, levels of mutation accumulation
within individual neurons vary substantially, and a subset of
neurons may accumulate levels of mutations during normal
aging that cross the phenotypic threshold. Furthermore, the
POLG mutator mice are not a good model for assessing
the role of mtDNA deletions in humans (see discussion
on this issue below). Thus, the role for somatic mtDNAParkinson’s Disease 5
mutations during normal aging and in neurodegenerative
disease remains an open question.
12.PointMutationsversusDeletions
It has been argued that large mtDNA deletions rather than
point mutations are the driving force behind the premature
aging phenotype in homozygous POLG mutator mice [91].
This argument was based on a “random mutation capture”
assay that demonstrated a large-fold relative increase in dele-
tions in the POLG mutator mice, but could not determine
theabsolutelevelsofmutations.Othermethodsrevealingthe
absolute level of deletions revealed that levels of deletions
are quite low even in the homozygous mutator mice,
especially when compared with the much higher level of
point mutations [86, 92]. Moreover, another mouse model,
“mito-mice”, genetically engineered to accumulate mtDNA
deletions, appear healthy without features of premature
aging despite reaching deletions in up to 30% of all mtDNA
molecules[93].ThereforeitappearslikelythatmtDNApoint
mutations rather than deletions drive the aging phenotype
in the POLG mutator mice. In SN neurons from both aged
controls and individuals with PD, both point mutations [71,
82] and large deletions [85, 86] accumulate to high levels.
In contrast, as discussed above, in the POLG mutator mice,
although point mutations reach high levels, absolute levels of
mtDNA deletions remain low. Thus the POLG mutator mice
may not be a valid model for understanding the functional
impact of mtDNA deletions.
13. POLG MutationsLead to
FamilialParkinsonism
First identiﬁed as a nuclear encoded protein in 1972,
POLG is the sole DNA polymerase in animal mitochondria
[94, 95]. Essential for synthesis, replication, and repair
of mtDNA, POLG contains three enzymatic activities: a
DNA polymerase activity, a 3  →5  exonuclease activity
involved in proofreading, and a 5 -deoxyribose phosphate
(dRP) lyase activity required for base excision repair [95].
Over 100 pathogenic mutations within the POLG gene have
been found to cause a vast array of both neurological and
nonneurological disorders including progressive external
ophthalmoplegia (PEO), ataxia, and Alpers’ syndrome [96].
POLG mutations have been linked to parkinsonism. Clinical
assessment of several families with PEO or premature
ovarian failure showed signiﬁcant co of POLG mutations
with levodopa responsive parkinsonism, and PET ﬁndings
were consistent with dopaminergic neuron loss [37, 38, 97].
Two missense mutations (G737R and R853W) in the POLG
gene were also detected in two siblings in a family with
early-onset familial parkinsonism [98]. Moreover, in a large-
scale systematic analysis of POLG gene in patients with
sporadic idiopathic PD, there is signiﬁcant clustering of rare
variants of the POLG1 CAG-repeat as compared with their
matched controls [99] .H o w e v e r ,as t u d yc o n d u c t e do na
large number of sporadic PD patients from UK and Italy
does not conform to the possibility of linking common
POLG polymorphisms in sporadic PD [100]. Nonetheless,
the association of POLG mutations in humans with SN
neuronal loss and parkinsonism, in combination with the
premature aging phenotype in the POLG mutator mice,
supports the hypothesis that the accumulation of somatic
mtDNA point mutations in SN neurons may be functionally
signiﬁcant and may contribute to the pathogenesis of PD.
14. Conclusions
Mitochondrial dysfunction appears to play an important
role in the pathogenesis of PD. Although the origin of
the mitochondrial dysfunction in PD is unknown, somatic
mtDNA point mutations and deletions have been found to
a c c u m u l a t ew i t ha g ea n dr e a c hh i g hl e v e l si nS Nn e u r o n s .
Experimental induction of POLG mutations cause the accu-
mulation of mtDNA mutations leading to a premature aging
phenotype in mutator mice. Although overt parkinsonism
has not been reported in these mice, mutations in the same
gene in humans can lead to dopaminergic dysfunction and
parkinsonism. Thus, the accumulation of somatic mtDNA
mutations in SN neurons may contribute to the pathogenesis
of PD. This hypothesis, if proven to be correct, implies that
strategies to block the accumulation of somatic mtDNA
mutations may be protective in PD.
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